Evidence map›Paper›PMID 39504355›Full record

ArticleScience translational medicine2024

Dysregulation of zebrin-II cell subtypes in the cerebellum is a shared feature across polyglutamine ataxia mouse models and patients.

Luke C Bartelt, Pawel M Switonski, Grażyna Adamek, Fabiana Longo, Juliana Carvalho, Lisa A Duvick, Sabrina I Jarrah, Hayley S McLoughlin, Daniel R Scoles, Stefan M Pulst and 4 more

Abstract read
In one paragraph

Article in Science translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Essential new insights into human cerebellar Purkinje cell biology from studies of essential tremor.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Luke C BarteltUniversity Program in Genetics & Genomics, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0001-8731-3680
Pawel M SwitonskiDepartment of Neuronal Cell Biology, Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland.ORCID 0000-0003-0690-6228
Grażyna AdamekDepartment of Neuronal Cell Biology, Institute of Bioorganic Chemistry, Polish Academy of Sciences, 61-704 Poznan, Poland.ORCID 0000-0002-8233-1473
Fabiana LongoDepartments of Pathology & Laboratory Medicine, Neurology, Biological Chemistry, and Neurobiology & Behavior, University of California, Irvine, Irvine, CA 92697, USA.
Juliana CarvalhoDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA.
Lisa A DuvickInstitute for Translational Neuroscience, and Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0009-0006-1453-4400
Sabrina I JarrahDepartment of Neurology, University of Michigan, Ann Arbor, MI 48109, USA.
Hayley S McLoughlinDepartment of Neurology, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0003-4279-2758
Daniel R ScolesDepartment of Neurology, University of Utah, Salt Lake City, UT 84132, USA.ORCID 0000-0002-3271-9912
Stefan M PulstDepartment of Neurology, University of Utah, Salt Lake City, UT 84132, USA.
Harry T OrrInstitute for Translational Neuroscience, and Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0001-6118-741X
Court HullDepartment of Neurobiology, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-0360-8367
Craig B LoweDepartment of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-6838-1976
Albert R La SpadaDepartments of Pathology & Laboratory Medicine, Neurology, Biological Chemistry, and Neurobiology & Behavior, University of California, Irvine, Irvine, CA 92697, USA.ORCID 0000-0001-6151-2964

Funding

SCA7 RETINAL DEGENERATION: MOLECULAR BASIS &THERAPYR01EY014061 · NEI · UNIVERSITY OF WASHINGTON · PI ALBERT R LA SPADA · 2002 to 2026
$8.4M
La Spada Outstanding Investigator AwardR35NS122140 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI ALBERT R LA SPADA · 2021 to 2026
$7.2M
Ataxin-2 complex proteins in neurodegeneration.R35NS127253 · NINDS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Stefan M. PULST · 2022 to 2026
$4.6M
Molecular genetics of neurodegenerative pathogenic and protective pathways: The SCA1 perspectiveR35NS127248 · NINDS · UNIVERSITY OF MINNESOTA · PI Harry T. Orr · 2022 to 2026
$3.9M
Spinocerebellar Ataxia Type 2 Gene and Gene ProductR37NS033123 · NINDS · UNIVERSITY OF UTAH · PI PULST, STEFAN M. · 2014 to 2020
$3.6M
RNA Granules in Cerebellar NeurodegenerationR01NS097903 · NINDS · UNIVERSITY OF UTAH · PI SCOLES, DANIEL R · 2017 to 2021
$2.7M
From a Long List to Causal Variants: High-Throughput Gene Regulatory Assays in Developing TissuesR35HG011332 · NHGRI · DUKE UNIVERSITY · PI LOWE, CRAIG BARRETT · 2020 to 2024
$2.3M
NEI NIH HHS R01 EY014061NHGRI NIH HHS R35 HG011332NINDS NIH HHS R01 NS097903NINDS NIH HHS R35 NS122140NINDS NIH HHS R35 NS127248NINDS NIH HHS R35 NS127253NINDS NIH HHS R37 NS033123
6 · The paper itself

Abstract

Spinocerebellar ataxia type 7 (SCA7) is a genetic neurodegenerative disorder caused by a CAG-polyglutamine repeat expansion. Purkinje cells (PCs) are central to the pathology of ataxias, but their low abundance in the cerebellum underrepresents their transcriptomes in sequencing assays. To address this issue, we developed a PC enrichment protocol and sequenced individual nuclei from mice and patients with SCA7. Single-nucleus RNA sequencing in SCA7-266Q mice revealed dysregulation of cell identity genes affecting glia and PCs. Specifically, genes marking zebrin-II PC subtypes accounted for the highest proportion of DEGs in symptomatic SCA7-266Q mice. These transcriptomic changes in SCA7-266Q mice were associated with increased numbers of inhibitory synapses as quantified by immunohistochemistry and reduced spiking of PCs in acute brain slices. Dysregulation of zebrin-II cell subtypes was the predominant signal in PCs of SCA7-266Q mice and was associated with the loss of zebrin-II striping in the cerebellum at motor symptom onset. We furthermore demonstrated zebrin-II stripe degradation in additional mouse models of polyglutamine ataxia and observed decreased zebrin-II expression in the cerebella of patients with SCA7. Our results suggest that a breakdown of zebrin subtype regulation is a shared pathological feature of polyglutamine ataxias.

Indexed as

CerebellumDisease Models, AnimalNerve Tissue ProteinsPeptidesPurkinje CellsAnimalsAtaxiaHumansMiceMice, TransgenicSpinocerebellar AtaxiasSynapsesTranscriptomeNerve Tissue ProteinsPeptidespolyglutaminezebrin II

Identifiers

PMID39504355
PMCPMC11806946

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.